{"id":"NCT03066804","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients","officialTitle":"A 24-week, Randomized, Double-blind, Multi-center, Parallel LCZ696 on NT-proBNP, Exercise Capacity, Symptoms and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-22","primaryCompletion":"2019-10-28","completion":"2019-10-28","firstPosted":"2017-02-28","resultsPosted":"2021-02-08","lastUpdate":"2021-10-11"},"enrollment":2572,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Heart Failure With Preserved Ejection Fraction"],"interventions":[{"type":"DRUG","name":"sacubitril/valsartan","otherNames":[]},{"type":"DRUG","name":"Enalapril","otherNames":[]},{"type":"DRUG","name":"Valsartan","otherNames":[]},{"type":"DRUG","name":"Placebo to match sacubitril/valsartan","otherNames":[]},{"type":"DRUG","name":"Placebo to match enalapril","otherNames":[]},{"type":"DRUG","name":"Placebo to match valsartan","otherNames":[]}],"arms":[{"label":"sacubitril/valsartan (LCZ696)","type":"EXPERIMENTAL"},{"label":"Comparator","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF symptoms in patients with heart failure with preserved ejection fraction (HFpEF).","primaryOutcome":{"measure":"Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12","timeFrame":"Baseline, week 12","effectByArm":[{"arm":"Sacubitril/Valsartan (LCZ696)","deltaMin":0.8218,"sd":null},{"arm":"Individualized Medical Therapy (IMT) Comparator","deltaMin":0.9828,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"45 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":16},"locations":{"siteCount":380,"countries":["United States","Argentina","Austria","Belgium","Brazil","Bulgaria","Canada","Colombia","Czechia","Denmark","Estonia","France","Germany","Guatemala","Hungary","India","Israel","Italy","Latvia","Lithuania","Mexico","Netherlands","Peru","Portugal","Romania","Russia","Serbia","Slovakia","Spain","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["34783839"],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=740"]},"adverseEventsSummary":{"seriousAny":{"events":186,"n":1280},"commonTop":["Glomerular filtration rate decreased","Hyperkalaemia","Renal impairment","Urine albumin/creatinine ratio increased","Haematuria"]}}